{"id":441,"date":"2010-05-12T04:00:00","date_gmt":"2010-05-12T04:00:00","guid":{"rendered":"https:\/\/www.lymphoma.ca\/?page_id=441"},"modified":"2020-02-26T14:45:57","modified_gmt":"2020-02-26T14:45:57","slug":"traitement-du-lnh-indolent-en-recidive","status":"publish","type":"page","link":"https:\/\/www.lymphoma.ca\/fr\/le-lymphome\/les-differents-types-de-lymphomes-non-hodgkiniens\/lymphome-non-hodgkinien\/traitement-du-lnh-indolent-en-recidive\/","title":{"rendered":"Traitement du LNH indolent en r\u00e9cidive"},"content":{"rendered":"<h2>Lymphome non hodgkinien indolent<\/h2>\n<p>La majeure partie des patients atteints de LNH indolent connaissent une r\u00e9cidive de leur maladie, en d\u00e9pit du traitement qu\u2019ils ont re\u00e7u. La dur\u00e9e entre le traitement et la r\u00e9cidive peut varier, mais elle est habituellement comprise entre 18&nbsp;mois et quatre ans.<\/p>\n<p>De nombreuses options sont possibles pour le traitement du LNH en r\u00e9cidive, et la d\u00e9cision d\u00e9pend de nombreux facteurs tels que l\u2019\u00e2ge, l\u2019\u00e9tat de sant\u00e9, le temps \u00e9coul\u00e9 entre la fin du traitement et la r\u00e9cidive, et le stade et le degr\u00e9 de diff\u00e9renciation du LNH.<\/p>\n<p>Les traitements possibles comprennent&nbsp;:<\/p>\n<ul>\n<li>la vigilance, qui peut repr\u00e9senter la meilleure option pour les patients dont les sympt\u00f4mes ne les g\u00eanent pas;<\/li>\n<li>la chimioth\u00e9rapie, qui est le traitement le plus courant pour les maladies r\u00e9cidivantes.<\/li>\n<li>Les anticorps monoclonaux tels que le rituximab (Rituxan<sup>MD<\/sup>) sont souvent utilis\u00e9s pour certains types de LNH r\u00e9cidivants, et ils sont g\u00e9n\u00e9ralement associ\u00e9s \u00e0 une chimioth\u00e9rapie pour augmenter l\u2019efficacit\u00e9 de cette derni\u00e8re, sans augmenter significativement les effets secondaires.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p>Lors d\u2019une r\u00e9cidive, le LNH indolent peut avoir chang\u00e9 ou s\u2019\u00eatre transform\u00e9 en une forme agressive de la maladie. Il peut devenir difficile de traiter des patients dont le LNH s\u2019est transform\u00e9. On peut les traiter avec une chimioth\u00e9rapie \u00e0 forte dose avec ou sans greffe de cellules souches du sang p\u00e9riph\u00e9rique. Ce type de greffe peut \u00e9galement \u00eatre combin\u00e9 \u00e0 une th\u00e9rapie par anticorps monoclonaux dans le but de d\u00e9truire toutes les cellules lymphomateuses r\u00e9siduelles de la moelle osseuse.<\/p>\n<p>Si un traitement \u00e0 forte dose n\u2019est pas possible, la prise en charge m\u00e9dicale visera probablement \u00e0 r\u00e9duire les sympt\u00f4mes; c\u2019est ce que l\u2019on appelle souvent le traitement palliatif.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lymphome non hodgkinien indolent La majeure partie des patients atteints de LNH indolent connaissent une r\u00e9cidive de leur maladie, en d\u00e9pit du traitement qu\u2019ils ont re\u00e7u. La dur\u00e9e entre le&#8230;<\/p>\n","protected":false},"author":6,"featured_media":0,"parent":380,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"page-sidebar.php","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-441","page","type-page","status-publish"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Traitement du LNH indolent en r\u00e9cidive - Lymphoma Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.lymphoma.ca\/lymphoma\/non-hodgkin-lymphoma\/treatment-goals\/treatment-for-relapsed-indolent-nhl\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Traitement du LNH indolent en r\u00e9cidive - Lymphoma Canada\" \/>\n<meta property=\"og:description\" content=\"Lymphome non hodgkinien indolent La majeure partie des patients atteints de LNH indolent connaissent une r\u00e9cidive de leur maladie, en d\u00e9pit du traitement qu\u2019ils ont re\u00e7u. La dur\u00e9e entre le...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.lymphoma.ca\/lymphoma\/non-hodgkin-lymphoma\/treatment-goals\/treatment-for-relapsed-indolent-nhl\/\" \/>\n<meta property=\"og:site_name\" content=\"Lymphoma Canada\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LymphomaCanada\" \/>\n<meta property=\"article:modified_time\" content=\"2020-02-26T14:45:57+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@lymphomacanada\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.lymphoma.ca\/lymphoma\/non-hodgkin-lymphoma\/treatment-goals\/treatment-for-relapsed-indolent-nhl\/\",\"url\":\"https:\/\/www.lymphoma.ca\/lymphoma\/non-hodgkin-lymphoma\/treatment-goals\/treatment-for-relapsed-indolent-nhl\/\",\"name\":\"Traitement du LNH indolent en r\u00e9cidive - Lymphoma Canada\",\"isPartOf\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#website\"},\"datePublished\":\"2010-05-12T04:00:00+00:00\",\"dateModified\":\"2020-02-26T14:45:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.lymphoma.ca\/lymphoma\/non-hodgkin-lymphoma\/treatment-goals\/treatment-for-relapsed-indolent-nhl\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.lymphoma.ca\/lymphoma\/non-hodgkin-lymphoma\/treatment-goals\/treatment-for-relapsed-indolent-nhl\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.lymphoma.ca\/lymphoma\/non-hodgkin-lymphoma\/treatment-goals\/treatment-for-relapsed-indolent-nhl\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.lymphoma.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lymphome\",\"item\":\"https:\/\/www.lymphoma.ca\/fr\/le-lymphome\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Les diff\u00e9rents types de lymphomes non hodgkiniens\",\"item\":\"https:\/\/www.lymphoma.ca\/fr\/le-lymphome\/les-differents-types-de-lymphomes-non-hodgkiniens\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Lymphome non-Hodgkinien\",\"item\":\"https:\/\/www.lymphoma.ca\/fr\/le-lymphome\/les-differents-types-de-lymphomes-non-hodgkiniens\/lymphome-non-hodgkinien\/\"},{\"@type\":\"ListItem\",\"position\":5,\"name\":\"Traitement du LNH indolent en r\u00e9cidive\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#website\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/\",\"name\":\"Lymphoma Canada\",\"description\":\"Information. Help. Hope.\",\"publisher\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.lymphoma.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#organization\",\"name\":\"Lymphoma Canada\",\"url\":\"https:\/\/www.lymphoma.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg\",\"contentUrl\":\"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg\",\"width\":343,\"height\":343,\"caption\":\"Lymphoma Canada\"},\"image\":{\"@id\":\"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LymphomaCanada\",\"https:\/\/x.com\/lymphomacanada\",\"https:\/\/www.linkedin.com\/company\/lymphoma-canada\/\",\"http:\/\/instagram.com\/lymphomacanada\",\"http:\/\/www.youtube.com\/user\/LymphomaTV\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Traitement du LNH indolent en r\u00e9cidive - Lymphoma Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.lymphoma.ca\/lymphoma\/non-hodgkin-lymphoma\/treatment-goals\/treatment-for-relapsed-indolent-nhl\/","og_locale":"fr_FR","og_type":"article","og_title":"Traitement du LNH indolent en r\u00e9cidive - Lymphoma Canada","og_description":"Lymphome non hodgkinien indolent La majeure partie des patients atteints de LNH indolent connaissent une r\u00e9cidive de leur maladie, en d\u00e9pit du traitement qu\u2019ils ont re\u00e7u. La dur\u00e9e entre le...","og_url":"https:\/\/www.lymphoma.ca\/lymphoma\/non-hodgkin-lymphoma\/treatment-goals\/treatment-for-relapsed-indolent-nhl\/","og_site_name":"Lymphoma Canada","article_publisher":"https:\/\/www.facebook.com\/LymphomaCanada","article_modified_time":"2020-02-26T14:45:57+00:00","twitter_card":"summary_large_image","twitter_site":"@lymphomacanada","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.lymphoma.ca\/lymphoma\/non-hodgkin-lymphoma\/treatment-goals\/treatment-for-relapsed-indolent-nhl\/","url":"https:\/\/www.lymphoma.ca\/lymphoma\/non-hodgkin-lymphoma\/treatment-goals\/treatment-for-relapsed-indolent-nhl\/","name":"Traitement du LNH indolent en r\u00e9cidive - Lymphoma Canada","isPartOf":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#website"},"datePublished":"2010-05-12T04:00:00+00:00","dateModified":"2020-02-26T14:45:57+00:00","breadcrumb":{"@id":"https:\/\/www.lymphoma.ca\/lymphoma\/non-hodgkin-lymphoma\/treatment-goals\/treatment-for-relapsed-indolent-nhl\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.lymphoma.ca\/lymphoma\/non-hodgkin-lymphoma\/treatment-goals\/treatment-for-relapsed-indolent-nhl\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.lymphoma.ca\/lymphoma\/non-hodgkin-lymphoma\/treatment-goals\/treatment-for-relapsed-indolent-nhl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.lymphoma.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Lymphome","item":"https:\/\/www.lymphoma.ca\/fr\/le-lymphome\/"},{"@type":"ListItem","position":3,"name":"Les diff\u00e9rents types de lymphomes non hodgkiniens","item":"https:\/\/www.lymphoma.ca\/fr\/le-lymphome\/les-differents-types-de-lymphomes-non-hodgkiniens\/"},{"@type":"ListItem","position":4,"name":"Lymphome non-Hodgkinien","item":"https:\/\/www.lymphoma.ca\/fr\/le-lymphome\/les-differents-types-de-lymphomes-non-hodgkiniens\/lymphome-non-hodgkinien\/"},{"@type":"ListItem","position":5,"name":"Traitement du LNH indolent en r\u00e9cidive"}]},{"@type":"WebSite","@id":"https:\/\/www.lymphoma.ca\/fr\/#website","url":"https:\/\/www.lymphoma.ca\/fr\/","name":"Lymphoma Canada","description":"Information. Help. Hope.","publisher":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.lymphoma.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.lymphoma.ca\/fr\/#organization","name":"Lymphoma Canada","url":"https:\/\/www.lymphoma.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg","contentUrl":"https:\/\/www.lymphoma.ca\/wp-content\/uploads\/2023\/05\/logo-lymphoma.jpg","width":343,"height":343,"caption":"Lymphoma Canada"},"image":{"@id":"https:\/\/www.lymphoma.ca\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LymphomaCanada","https:\/\/x.com\/lymphomacanada","https:\/\/www.linkedin.com\/company\/lymphoma-canada\/","http:\/\/instagram.com\/lymphomacanada","http:\/\/www.youtube.com\/user\/LymphomaTV"]}]}},"_links":{"self":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/pages\/441","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/comments?post=441"}],"version-history":[{"count":1,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/pages\/441\/revisions"}],"predecessor-version":[{"id":3282,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/pages\/441\/revisions\/3282"}],"up":[{"embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/pages\/380"}],"wp:attachment":[{"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/media?parent=441"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/categories?post=441"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lymphoma.ca\/fr\/wp-json\/wp\/v2\/tags?post=441"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}